| __timestamp | Bio-Techne Corporation | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 125883000 |
| Thursday, January 1, 2015 | 144969000 | 69036000 |
| Friday, January 1, 2016 | 162364000 | 72700000 |
| Sunday, January 1, 2017 | 188462000 | 105700000 |
| Monday, January 1, 2018 | 210850000 | 198700000 |
| Tuesday, January 1, 2019 | 240515000 | 117600000 |
| Wednesday, January 1, 2020 | 255497000 | 108100000 |
| Friday, January 1, 2021 | 298182000 | 122500000 |
| Saturday, January 1, 2022 | 349103000 | 146700000 |
| Sunday, January 1, 2023 | 366887000 | 257500000 |
| Monday, January 1, 2024 | 389335000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and Bio-Techne Corporation from 2014 to 2023. Over this period, Bio-Techne's cost of revenue has surged by approximately 266%, peaking in 2023, while United Therapeutics experienced a more modest increase of around 105% until 2022, with a notable spike in 2023. This suggests Bio-Techne's aggressive expansion or increased operational costs, whereas United Therapeutics maintained a steadier cost trajectory. Interestingly, data for United Therapeutics in 2024 is missing, indicating potential reporting delays or strategic shifts. Understanding these trends provides valuable insights into each company's operational strategies and market positioning, offering investors a clearer picture of their financial health and efficiency.
Novo Nordisk A/S vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and United Therapeutics Corporation's Expenses
Cost of Revenue: Key Insights for United Therapeutics Corporation and Walgreens Boots Alliance, Inc.
United Therapeutics Corporation vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: United Therapeutics Corporation and MorphoSys AG
Analyzing Cost of Revenue: United Therapeutics Corporation and Wave Life Sciences Ltd.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioMarin Pharmaceutical Inc.
Bio-Techne Corporation vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.